BTAI Stock — BioXcel Therapeutics Inc

BioXcel Therapeutics Inc (BTAI)

Updated October 8, 2026.

BTAI is a Stock. Total return is -100.0% over the past 8.6 years, 322.4 points behind SPY at 222.4%.

BioXcel Therapeutics is a biopharmaceutical company developing AI-driven medicines in neuroscience and immuno-oncology, with an approved schizophrenia and bipolar disorder treatment (IGALMI) and multiple candidates in clinical trials for conditions including agitation, dementia-related symptoms, and various cancers. The company does not currently distribute to shareholders. As of August 2026, BioXcel Therapeutics filed for Chapter 11 bankruptcy reorganization.

BTAI performance versus SPY

Price and return data through 2026-10-08.

Total return is -100.0% over the past 8.6 years, 322.4 points behind SPY at 222.4%. Over the past year its total return — price change plus distributions reinvested — is -98.2%. Its deepest 1-year drawdown was 98.7%.

BTAI key facts

Asset type

Stock

Asset class

Equity

Inception date

03/08/2018

Distribution frequency

None

Last close

$0.05 (stale; as of 2026-10-08)

Market cap

$1,499,533

Average volume

70578.0

Beta

0.188

Payout ratio

0.0%

EPS

$-2.58

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BTAI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 98.7%.

Who may consider BTAI — and who may not

It is a weaker fit for investors who need monthly cash flow (BTAI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BTAI

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions